N. Azrolan

发表

Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme

I. Mcintosh, J. Wagner, K. Lasseter, 2007, Drug Metabolism and Disposition.

Protective Effect of the Immunosuppressant Sirolimus Against Aortic Atherosclerosis In Apo E‐Deficient Mice

S. Adelman, N. Azrolan, M. Basso, 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic mice.

A. Tall, J. Breslow, A. Walsh, 1993, The Journal of clinical investigation.

Reduction of lipoprotein(a) following treatment with lovastatin in patients with unremitting nephrotic syndrome.

E. Friedman, A. Bostom, N. Azrolan, 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

The full induction of human apoprotein A-I gene expression by the experimental nephrotic syndrome in transgenic mice depends on cis-acting elements in the proximal 256 base-pair promoter region and the trans-acting factor early growth response factor 1.

J. Milbrandt, E. Fisher, M. Madaio, 1998, The Journal of clinical investigation.

Intestinal expression of the human apoA-I gene in transgenic mice is controlled by a DNA region 3' to the gene in the promoter of the adjacent convergently transcribed apoC-III gene.

J. Breslow, A. Walsh, K. Wang, 1993, Journal of lipid research.

Effects of omeprazole on plasma levels of raltegravir.

H. Teppler, J. Wagner, B. Nguyen, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir

H. Greenberg, J. Wagner, K. Gottesdiener, 2008, Antimicrobial Agents and Chemotherapy.

Probucol decreases apolipoprotein A-I transport rate and increases high density lipoprotein cholesteryl ester fractional catabolic rate in control and human apolipoprotein A-I transgenic mice.

J. Breslow, A. Walsh, T. Hayek, 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

mRN 4 in human hepatoma cell lines

J. Breslow, N. Azrolan, 2002 .

Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice.

J. Breslow, A. Walsh, Y. Ito, 1990, Science.

Characterization of the mouse apolipoprotein Apoa-1/Apoc-3 gene locus: genomic, mRNA, and protein sequences with comparisons to other species.

J. Breslow, K. Aalto-Setälä, J. Januzzi, 1992, Genomics.

Dietary Fat Elevates Hepatic ApoA-I Production by Increasing the Fraction of Apolipoprotein A-I mRNA in the Translating Pool (*)

E. Fisher, J. Breslow, N. Azrolan, 1995, The Journal of Biological Chemistry.

A solution hybridization/RNase protection assay with riboprobes to determine absolute levels of apoB, A-I, and E mRNA in human hepatoma cell lines.

J. Breslow, N. Azrolan, 1990, Journal of lipid research.

Plasma Ip(a) concentration is inversely correlated with the ratio of Kringle IV/Kringle V encoding domains in the apo(a) gene.

J. Breslow, D. Gavish, N. Azrolan, 1989, The Journal of clinical investigation.

Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels in renal transplant recipients. Evidence for renal involvement in the maintenance of LDL-C and the elevation of Lp(a) concentrations in hemodialysis patients.

E. Friedman, T. Hayek, N. Azrolan, 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

Lipoprotein(a) in diet-induced atherosclerosis in nonhuman primates.

R. Nachman, D. Gavish, N. Azrolan, 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

N-acetylcysteine and lipoprotein(a)

J. Breslow, A. Bostom, N. Azrolan, 1992, The Lancet.

Plasma lipoprotein(a) concentration is controlled by apolipoprotein(a) (apo(a)) protein size and the abundance of hepatic apo(a) mRNA in a cynomolgus monkey model.

J. Breslow, D. Gavish, N. Azrolan, 1991, The Journal of biological chemistry.

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

W. Bridson, J. Wagner, K. Gottesdiener, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

ApoA-I knockout mice: characterization of HDL metabolism in homozygotes and identification of a post-RNA mechanism of apoA-I up-regulation in heterozygotes.

A. Tall, S. Eisenberg, J. Breslow, 1997, Journal of lipid research.

A Double-Blind, Randomized, Controlled, Multicenter Safety and Immunogenicity Study of a Refrigerator-Stable Formulation of Zostavax

Ivan S. F. Chan, S. Sutradhar, I. Chan, 2007, Clinical and Vaccine Immunology.

Human placental tissue expresses a novel 22.7 kDa apolipoprotein A-I-like protein.

S. Handwerger, G. Anantharamaiah, B. Richardson, 1996, Biochemistry.

Effects of omeprazole on plasma levels of raltegravir.

H. Teppler, B. Nguyen, M. Iwamoto, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cellular distribution of cholesterogenesis‐linked, phosphoisoprenylated proteins in proliferating cells

L. Sepp-Lorenzino, N. Azrolan, P. Coleman, 1989, FEBS letters.